PolyPid to Present at Israel Controlled Release Society Conference: Insights into PLEX Technology
ByAinvest
Wednesday, Sep 3, 2025 1:22 am ET1min read
PYPD--
The company's proprietary PLEX technology enables controlled, prolonged drug release, and PolyPid plans to submit a New Drug Application (NDA) for its lead product candidate, D-PLEX₁₀₀, which aims to prevent surgical site infections after colorectal surgeries, expected in early 2026. The company also has a pipeline focused on oncology, obesity, and diabetes [1].
PolyPid's presentation at the ICRS Conference showcases the company's commitment to innovation in drug delivery and its progress in advancing surgical outcomes. The presentation will detail the successful Phase III trial of D-PLEX₁₀₀, highlighting the company's momentum towards potential regulatory approval [1].
However, the submission of the NDA for D-PLEX₁₀₀ is not expected until early 2026, suggesting potential delays in bringing the product to market. Additionally, the focus on a single product candidate for surgical site infections may indicate a lack of diversification in the company's drug development pipeline, making it vulnerable to potential market or regulatory setbacks [1].
References:
[1] https://www.quiverquant.com/news/PolyPid+Ltd.+to+Present+at+Israel+Controlled+Release+Society+Conference+on+Advances+in+Drug+Delivery+Technology
PolyPid Ltd. (PYPD) will present at the 14th Israel Controlled Release Society Conference. Deputy CEO Dalit Hazan will present "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial." The company specializes in advanced drug delivery systems to improve surgical outcomes. PolyPid plans to submit an NDA for its lead product candidate, D-PLEX, by early 2026.
PolyPid Ltd. (PYPD), a late-stage biopharmaceutical company focused on enhancing surgical outcomes, has announced that Deputy CEO Dalit Hazan will present at the 14th Israel Controlled Release Society (ICRS) Conference. The presentation, titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial," will take place on September 7, 2025, from 5:25 PM to 5:45 PM local time as part of a session on advances in targeted drug delivery [1].The company's proprietary PLEX technology enables controlled, prolonged drug release, and PolyPid plans to submit a New Drug Application (NDA) for its lead product candidate, D-PLEX₁₀₀, which aims to prevent surgical site infections after colorectal surgeries, expected in early 2026. The company also has a pipeline focused on oncology, obesity, and diabetes [1].
PolyPid's presentation at the ICRS Conference showcases the company's commitment to innovation in drug delivery and its progress in advancing surgical outcomes. The presentation will detail the successful Phase III trial of D-PLEX₁₀₀, highlighting the company's momentum towards potential regulatory approval [1].
However, the submission of the NDA for D-PLEX₁₀₀ is not expected until early 2026, suggesting potential delays in bringing the product to market. Additionally, the focus on a single product candidate for surgical site infections may indicate a lack of diversification in the company's drug development pipeline, making it vulnerable to potential market or regulatory setbacks [1].
References:
[1] https://www.quiverquant.com/news/PolyPid+Ltd.+to+Present+at+Israel+Controlled+Release+Society+Conference+on+Advances+in+Drug+Delivery+Technology
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet